Clinical trial
A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease
NCT01255046 is registered in ClinicalTrials.gov with Sinphar Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease
- Lead sponsor
- Sinphar Pharmaceutical Co., Ltd
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 31, 2015
- Completion date
- Not reported
- Enrollment
- 136 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.